Overview
SLU-PP-332 is tracked as a supplement in Milligram's compound library. Synthetic ERRγ (estrogen-related receptor gamma) agonist.
With a half-life of ~5 hours, SLU-PP-332 requires daily administration in most observed protocols. Taken orally, it has a bioavailability of approximately 60% via its primary route.
Estimated half-life approximately 4–6 hours based on preclinical pharmacokinetic data. Oral administration. Limited published human PK data. One-compartment model.
Mechanism of Action
SLU-PP-332's pharmacological activity involves the following key pathways:
Primary Mechanism
SLU-PP-332 exerts its effects through its established pharmacological pathway. Its mechanism has been characterized in published research.
Bioavailability Profile
SLU-PP-332 has high oral bioavailability, which influences dosing strategy and administration timing.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
10 mg/day
Route
Oral
Frequency
2-3 times daily
Duration
Ongoing
Dose
50 mg/day
Route
Oral
Frequency
2-3 times daily
Duration
Ongoing
Frequently Asked Questions
What is SLU-PP-332 and how does it work?
SLU-PP-332 is a synthetic small-molecule agonist that activates estrogen-related receptors (ERRα, ERRβ, and ERRγ) – nuclear receptors that regulate energy metabolism and mitochondrial function. It is classified as an "exercise mimetic" because it activates the same genetic programs that aerobic exercise triggers, particularly the ERRα-dependent DDIT4 pathway. It is not a peptide, hormone, or SARM.
Is SLU-PP-332 approved for human use?
SLU-PP-332 has not been approved for human use and remains a research compound as of 2026. Published studies have been conducted in mouse models, where it demonstrated increased energy expenditure, enhanced fatty acid oxidation, and improved exercise endurance. Community use has preceded formal human clinical trials, and long-term safety data in humans does not yet exist.
What does SLU-PP-332 do for metabolism and fat loss?
In preclinical research, SLU-PP-332 increased energy expenditure, enhanced fatty acid oxidation, and reduced fat mass accumulation. It also increased the proportion of type IIa oxidative muscle fibers in mice – the fiber type associated with endurance and sustained effort. These metabolic effects mimic the adaptations normally produced by consistent aerobic exercise.
What is the half-life of SLU-PP-332?
The half-life of SLU-PP-332 is estimated at approximately 4 hours based on available pharmacokinetic data, though comprehensive human PK studies have not been published. This relatively short half-life means split dosing – typically 2 to 3 times daily – is commonly observed in community protocols to maintain more stable plasma levels throughout the day.
What are the reported side effects of SLU-PP-332?
As a novel research compound, the side effect profile of SLU-PP-332 is not well established. Preclinical studies have not reported serious adverse events. Community reports mention mild and dose-dependent effects including temporary energy fluctuations during the adaptation period, occasional nausea at higher doses, and rare headaches – all consistent with metabolic activation. Long-term safety remains unknown.
Can SLU-PP-332 replace exercise?
While SLU-PP-332 activates exercise-related metabolic pathways at the cellular level, it does not replicate the full spectrum of exercise benefits including cardiovascular conditioning, mechanical loading for bone density, and neuromuscular coordination. Research positions it as a tool that may complement physical activity or provide metabolic support when exercise capacity is limited – not a complete substitute.